GNFT

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Genfit S.A.

NASDAQ | GNFT

4.85

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 19, 2025)

$244.43M

Market Cap

-

P/E Ratio

-0.9

EPS

$4.92

52 Week High

$2.55

52 Week Low

HEALTHCARE

Sector

GNFT Chart

Recent Chart
Price Action

GNFT Technicals

Tags:

GNFT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $67M
Total Revenue $67M
Cost Of Revenue $300K
Costof Goods And Services Sold $300K
Operating Income $3.3M
Selling General And Administrative $19M
Research And Development $47M
Operating Expenses $63M
Investment Income Net -
Net Interest Income -$2.2M
Interest Income $1.8M
Interest Expense $4.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.7M
Income Before Tax $1.8M
Income Tax Expense $340K
Interest And Debt Expense -
Net Income From Continuing Operations $1.5M
Comprehensive Income Net Of Tax -
Ebit $6.6M
Ebitda $8.3M
Net Income $1.5M

Revenue & Profitability

Earnings Performance

GNFT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (EUR)
Total Assets $151M
Total Current Assets $93M
Cash And Cash Equivalents At Carrying Value $82M
Cash And Short Term Investments $82M
Inventory $4K
Current Net Receivables $7.6M
Total Non Current Assets $59M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $48M
Intangible Assets Excluding Goodwill $48M
Goodwill -
Investments -
Long Term Investments $1.9M
Short Term Investments $1.2M
Other Current Assets $3.4M
Other Non Current Assets -
Total Liabilities $82M
Total Current Liabilities $75M
Current Accounts Payable $18M
Deferred Revenue -
Current Debt -
Short Term Debt $57M
Total Non Current Liabilities $7M
Capital Lease Obligations $5.1M
Long Term Debt $1.6M
Current Long Term Debt $55M
Long Term Debt Noncurrent -
Short Long Term Debt Total $62M
Other Current Liabilities $194K
Other Non Current Liabilities -
Total Shareholder Equity $69M
Treasury Stock -
Retained Earnings -$391M
Common Stock $12M
Common Stock Shares Outstanding $50M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (EUR)
Operating Cashflow $16M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.7M
Capital Expenditures $979K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$1M
Cashflow From Financing -$11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $1.5M

yearly Income Statement (As of Dec 31, 2024)

Field Value (EUR)
Gross Profit $67M
Total Revenue $67M
Cost Of Revenue $300K
Costof Goods And Services Sold $300K
Operating Income $3.3M
Selling General And Administrative $19M
Research And Development $47M
Operating Expenses $63M
Investment Income Net -
Net Interest Income -$2.2M
Interest Income $1.8M
Interest Expense $4.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.7M
Income Before Tax $1.8M
Income Tax Expense $340K
Interest And Debt Expense -
Net Income From Continuing Operations $1.5M
Comprehensive Income Net Of Tax -
Ebit $6.6M
Ebitda $8.3M
Net Income $1.5M

GNFT Profile

Genfit S.A. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Genfit S.A. is a biopharmaceutical firm based in Loos, France, specializing in the discovery and development of innovative therapies and diagnostic solutions for metabolic and liver diseases, particularly non-alcoholic steatohepatitis (NASH). Harnessing proprietary technology platforms, Genfit is advancing a promising pipeline of drug candidates aimed at addressing significant unmet medical needs in liver health. The company is strategically positioned within the biopharmaceutical sector and is proactively seeking partnerships to enhance its market reach and solidify its impact in the healthcare landscape.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+51.88%
$1.61
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
AMZE
+23.68%
$0.48
TLRY
-22.27%
$0.80
IPG
-1.95%
$24.57
BITF
+10.80%
$3.43
INTC
+9.08%
$40.15
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
TSLA
+1.71%
$426.58
BYND
-4.59%
$0.97
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
KVUE
+1.11%
$17.22
RUBI
-26.31%
$0.15
CLSK
+11.97%
$15.06
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BMNR
+3.76%
$32.93
PLUG
+2.27%
$2.02
BIYA
+10.67%
$0.27
INHD
-0.79%
$0.22
SRM
+53.27%
$10.30
CHR
-2.55%
$0.04
ONMD
+31.69%
$1.87
SNAP
+0.37%
$7.63
WULF
+4.51%
$15.51
TWOH
0.00%
$0.00
BMNU
+3.72%
$7.79
CIFR
+7.41%
$20.56
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AAL
+0.72%
$14.03
MARA
+4.18%
$11.57
VALE
+0.79%
$12.61
ONDS
-4.36%
$7.88
SOFI
+4.31%
$29.72
GPUS
-9.06%
$0.30
NIO
+1.09%
$5.51
F
+0.61%
$13.27
AFMD
-34.94%
$0.18
DEFT
+9.24%
$1.51
BURU
+7.72%
$0.22
APLD
+5.05%
$24.94
BTBT
+1.15%
$2.34
KWM
+17.30%
$0.77
GOOGL
-0.26%
$319.09
SMX
+244.97%
$60.02
AMZN
+1.77%
$233.22
CRCL
+9.28%
$79.38
BTG
+3.25%
$4.61
AIIO
-9.09%
$0.70
GRYP
-10.38%
$1.38
DVLT
-7.05%
$1.97
HBI
-2.20%
$6.44
ACHR
+4.79%
$7.84
MODV
-25.22%
$0.43
BAC
+1.28%
$53.67
AMD
+1.53%
$217.53
IBRX
+9.15%
$2.32
CAN
+10.07%
$1.01
GRAB
+2.34%
$5.44
RIOT
+6.97%
$16.00
IREN
-1.31%
$47.81
AG
+12.47%
$15.19
NGD
+5.92%
$8.30
KDLY
+7.20%
$0.49
DNN
+0.39%
$2.57
VEEE
+50.56%
$2.68
YCBD
-3.44%
$0.53
NVO
+1.21%
$49.30
CRCA
+17.43%
$4.32
AMC
+5.99%
$2.43
TMC
+17.92%
$6.87
GOOG
-0.34%
$319.17
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
RIG
+1.97%
$4.38
PFE
+0.05%
$25.72
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
RIVN
+4.82%
$16.96
ZAPP
-46.30%
$0.15
AGNC
-0.80%
$10.47
CDE
+6.08%
$17.17
SMR
+4.38%
$19.87
SNDK
+3.83%
$223.28
MSTR
+0.01%
$175.66
WBD
+0.94%
$24.10
BTE
+2.84%
$3.25
ITUB
+2.02%
$7.81
EXK
+15.28%
$9.93
HL
+4.56%
$16.69
PLTR
+0.80%
$167.11
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+51.88%
$1.61
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
AMZE
+23.68%
$0.48
TLRY
-22.27%
$0.80
IPG
-1.95%
$24.57
BITF
+10.80%
$3.43
INTC
+9.08%
$40.15
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
TSLA
+1.71%
$426.58
BYND
-4.59%
$0.97
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
KVUE
+1.11%
$17.22
RUBI
-26.31%
$0.15
CLSK
+11.97%
$15.06
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
BMNR
+3.76%
$32.93
PLUG
+2.27%
$2.02
BIYA
+10.67%
$0.27
INHD
-0.79%
$0.22
SRM
+53.27%
$10.30
CHR
-2.55%
$0.04
ONMD
+31.69%
$1.87
SNAP
+0.37%
$7.63
WULF
+4.51%
$15.51
TWOH
0.00%
$0.00
BMNU
+3.72%
$7.79
CIFR
+7.41%
$20.56
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AAL
+0.72%
$14.03
MARA
+4.18%
$11.57
VALE
+0.79%
$12.61
ONDS
-4.36%
$7.88
SOFI
+4.31%
$29.72
GPUS
-9.06%
$0.30
NIO
+1.09%
$5.51
F
+0.61%
$13.27
AFMD
-34.94%
$0.18
DEFT
+9.24%
$1.51
BURU
+7.72%
$0.22
APLD
+5.05%
$24.94
BTBT
+1.15%
$2.34
KWM
+17.30%
$0.77
GOOGL
-0.26%
$319.09
SMX
+244.97%
$60.02
AMZN
+1.77%
$233.22
CRCL
+9.28%
$79.38
BTG
+3.25%
$4.61
AIIO
-9.09%
$0.70
GRYP
-10.38%
$1.38
DVLT
-7.05%
$1.97
HBI
-2.20%
$6.44
ACHR
+4.79%
$7.84
MODV
-25.22%
$0.43
BAC
+1.28%
$53.67
AMD
+1.53%
$217.53
IBRX
+9.15%
$2.32
CAN
+10.07%
$1.01
GRAB
+2.34%
$5.44
RIOT
+6.97%
$16.00
IREN
-1.31%
$47.81
AG
+12.47%
$15.19
NGD
+5.92%
$8.30
KDLY
+7.20%
$0.49
DNN
+0.39%
$2.57
VEEE
+50.56%
$2.68
YCBD
-3.44%
$0.53
NVO
+1.21%
$49.30
CRCA
+17.43%
$4.32
AMC
+5.99%
$2.43
TMC
+17.92%
$6.87
GOOG
-0.34%
$319.17
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
RIG
+1.97%
$4.38
PFE
+0.05%
$25.72
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
RIVN
+4.82%
$16.96
ZAPP
-46.30%
$0.15
AGNC
-0.80%
$10.47
CDE
+6.08%
$17.17
SMR
+4.38%
$19.87
SNDK
+3.83%
$223.28
MSTR
+0.01%
$175.66
WBD
+0.94%
$24.10
BTE
+2.84%
$3.25
ITUB
+2.02%
$7.81
EXK
+15.28%
$9.93
HL
+4.56%
$16.69
PLTR
+0.80%
$167.11
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.